 |
Welcome to Cylex where we are
committed to the continued advancement of transplant
medicine.
Cylex is a global life sciences
company focused on the development, manufacture and
commercialization of in vitro diagnostic products
intended to illuminate immunity in the area of transplant
medicine. The Company has developed patented technology
that provides an innovative platform to simply and
reproducibly assess immune cell function, thus providing
crucial insight for individualized transplant patient
management.
This patented
technology, as part of a global immune status
monitoring strategy has been used to help identify
kidney, liver, lung and heart transplant patients
with low immune response – having the potential to
lead to infection. Being in the know gives you crucial
insight for individualized patient management. |
|
Message from the President
Welcome to the Cylex Web Site
The principal goal of Cylex is to
bring together the people and resources required to research,
develop and market innovative, high quality products that
clinicians can include in their transplant patient monitoring
test strategy. Our goal is to illuminate immunity to improve
health. We do that every day with ImmuKnow®, the only
FDA-cleared assay that detects changes in global immune
function over time.
This web site contains a wealth of information that will
enable you to get to know ImmuKnow better. For example, you
can learn about ImmuKnow and how it helps clinicians identify
transplant patients at risk of infection due to over-immunosuppression
by visiting the Health Care Professional section. Or, if
you are a patient interested in learning about ImmuKnow and
how it provides your doctors with crucial insight for individualized
patient management, you can visit the Patients portion of
the site. There are many ways to learn about Cylex and ImmuKnow
– I invite you to explore them all.
Since the life sciences
industry is fast-paced and ever changing, we make every effort
to update our site frequently, so please come back often.
And remember, we value your opinions. We hope you enjoy
your visit.
Sincerely,
Brad L. Stewart
Chairman, CEO and President |